[Neytumorin as biomodular onco-therapy--allegations without documentation]

Area of Science:

• Biotechnology
• Immunology
• Oncology

Context:

• NeyTumorin is a product developed by Vitorgan-Pharmaceutical Company, based on K.E. Theurer's Cytoplasmatic Therapy.
• It is composed of peptides and proteins from 15 different organs of fetal and young pigs and cows.
• The therapy is indicated for cancer prevention and treatment, with costs ranging from DM 16,500 to over DM 100,000.

Purpose:

• To evaluate the claimed efficacy and mechanism of action of NeyTumorin as a biological response modifier for cancer treatment.
• To assess the scientific basis for the purported "hygiogenization" of disturbed metabolism and immunogenic/immuno-modulatory effects.

Summary:

• The components of NeyTumorin are not precisely defined.
• Preclinical data supporting direct cytostatic and immunomodulatory effects are insufficient, often using high concentrations.
• Clinical studies, including prospective randomized trials, are inconclusive due to inadequate documentation, failing to prove the claimed mechanism or clinical efficacy.

Impact:

• The lack of defined components and insufficient scientific evidence raises concerns about NeyTumorin's safety and effectiveness.
• Further rigorous, well-documented research is needed to validate the therapeutic claims of NeyTumorin.
• This analysis highlights the importance of robust scientific validation for novel cancer therapies.